Mereo BioPharma Group plc
MREO
$2.30
$0.177.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | 24.36% |
| Gross Profit | -- | -- | -- | -- | 252.73% |
| SG&A Expenses | 79.43% | 8.67% | 194.79% | -8.43% | -53.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.60% | 1.80% | 35.42% | -13.64% | -39.06% |
| Operating Income | -108.50% | -1.80% | -6,450.00% | 13.64% | 46.63% |
| Income Before Tax | 26.92% | -129.69% | -599.89% | 25.88% | -1.65% |
| Income Tax Expenses | -- | -- | -- | -- | -734.84% |
| Earnings from Continuing Operations | 22.65% | -129.69% | -599.89% | 25.88% | 4.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.65% | -129.69% | -599.89% | 25.88% | 4.80% |
| EBIT | -108.50% | -1.80% | -6,450.00% | 13.64% | 46.63% |
| EBITDA | -111.10% | -1.87% | -28,537.21% | 14.17% | 47.68% |
| EPS Basic | 30.11% | -104.19% | -519.42% | 33.99% | 15.34% |
| Normalized Basic EPS | 34.11% | -104.36% | -518.39% | 34.05% | 9.45% |
| EPS Diluted | 30.11% | -104.19% | -519.42% | 33.99% | 23.23% |
| Normalized Diluted EPS | 34.11% | -104.36% | -518.39% | 34.05% | 9.45% |
| Average Basic Shares Outstanding | 10.75% | 12.43% | 13.26% | 12.24% | 12.42% |
| Average Diluted Shares Outstanding | 10.75% | 12.43% | 13.26% | 12.24% | 12.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |